Amgen AMGN
Amgen is a biopharmaceutical company that develops and commercializes innovative medicines for serious diseases such as cancer, inflammation, and bone disorders, with a model based on R&D and the sale of patented products and biosimilars. Amgen shows a solid profile with an ROE of 91.47% and an operating margin of 35.55%, although its valuation (P/E 25.77) and earnings growth of 64.9% warrant caution; momentum is very strong (9.13).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Amgen is a biopharmaceutical company that develops and commercializes innovative medicines for serious diseases such as cancer, inflammation, and bone disorders, with a model based on R&D and the sale of patented products and biosimilars. Amgen shows a solid profile with an ROE of 91.47% and an operating margin of 35.55%, although its valuation (P/E 25.77) and earnings growth of 64.9% warrant caution; momentum is very strong (9.13).
Score by category
| Category | Score |
|---|---|
| Financial health | 7.0 |
| Quality / Moat | 8.2 |
| Valuation | 4.9 |
| Growth | 8.1 |
| Dividend | 6.8 |
| Momentum | 9.1 |
| Risk & Context | 8.3 |
OVERALL SCORE: 7.3/10
Context and risks
Amgen operates in the US pharmaceutical sector, subject to regulatory pressure on drug pricing (Inflation Reduction Act) and patent litigation, a structural sector risk that no financial metric captures.
News considered in the analysis
- Why Amgen’s Pipeline Just Got More Interesting — Comentario genérico sobre el pipeline, sin datos concretos de ensayos o aprobaciones; impacto moderado y parcialmente descontado.
- Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back — Operación inmobiliaria menor (sale-leaseback) sin impacto material en beneficios o valoración.
- Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. — Listículo/opinión general sobre el sector biotech sin información específica de Amgen.
- 2 Healthcare Stocks That Just Delivered Great News for Investors — Artículo genérico de selección de valores sin noticia concreta y verificable sobre Amgen.
- Amgen’s Deerfield office campus sold to Mesirow for $151M in sale-leaseback deal — Duplicado de la operación inmobiliaria; sin impacto material.
Verdict: Hold; quality is excellent but valuation does not offer enough margin of safety to add positions.
Main risk: US drug pricing regulatory pressure and patent litigation, which could compress Amgen's future margins.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →